Determining Duration of HER2-Targeted Therapy Using Stem Cell Extinction Models

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Riley, Lindsay ^a   Zhou, Hua ^b   Lange, Kenneth ^a,c   Sinsheimer, Janet S ^a,d   Sehl, Mary E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER STEM CELL; CELL DEATH; CELL DEDIFFERENTIATION; CELL POPULATION; DRUG SENSITIVITY; MATHEMATICAL MODEL; MOLECULARLY TARGETED THERAPY; PREDICTION; QUANTITATIVE ANALYSIS; TREATMENT DURATION; TUMOR CELL; TUMOR VOLUME;

BREAST NEOPLASMS; CELL DEATH; CELL DIFFERENTIATION; CHEMOTHERAPY, ADJUVANT; HUMANS; LIKELIHOOD FUNCTIONS; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; NEOPLASTIC STEM CELLS; RECEPTOR, ERBB-2; TIME FACTORS;

EID: 84871678211     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046613     Document Type: Article

References (29)

1. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792.
2. Slamon D, Eierman W, Robert N, Pienkowski T, Martin M, et al. (2005) Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC → T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC → TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat (suppl 1): S5.
3. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF, (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983-3988.
4. Korkaya H, Paulson A, Iovino F, Wicha MS, (2008) HER2 regulates the mammary/stem progenitor cell population driving tumorigenesis and invasion. Oncogene 27: 6120-6130.
5. Magnifico A, Albano L, Campaner S, Delia D, Castiglioni F, et al. (2009) Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab. Clin Cancer Res 15: 2010-2021.
6. Korkaya H, Wicha MS, (2009) HER-2, notch, and breast cancer stem cells: targeting an axis of evil. Clin Cancer Res 15: 1845-1847.
7. Liu S, Wicha MS, (2010) Targeting breast cancer stem cells. J Clin Oncol 28: 4006-4012.
8. McDermott SP, Wicha MS, (2010) Targeting breast cancer stem cells. Mol Oncol 4: 404-419.
9. Wicha MS, (2009) Targeting breast cancer stem cells. Breast 18Suppl 3: S56-S58.
10. Paik S, Kim C, Wolmark N, (2008) HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med 358: 1409-1411.
11. Ferguson TS (1996)A Course in Large Sample Theory. New York: Chapman & Hall/CRC. 256 p.
12. Sehl ME, Sinsheimer JS, Zhou H, Lange KL, (2009) Differential destruction of stem cells: Implications for targeted cancer stem cell therapy. Cancer Res 69: 9481-9489.
13. Sehl M, Zhou H, Sinsheimer JS, Lange KL, (2011) Extinction models for cancer stem cell therapy. Math Biosci 234: 132-146.
14. Sehl ME, Alekseyenko AL, Lange KL, (2009) Accurate stochastic simulation via the step anticipation τ-leaping (SAL) algorithm. J Comput Biol 16: 1195-1208.
15. Meyskens FL, Thomson SP, Moon TE, (1984) Quantitation of the number of cells within tumor colonies in semisolid medium and their growth as oblate spheroids. Cancer Res 44: 271-277.
16. Norton L, (1988) A Gompertzian model of human breast cancer growth. Cancer Res 48: 7067-7071.
17. Hudis CA, (2007) Trastuzumab - mechanism of action and use in clinical practice. N Engl J Med 357: 39-51.
18. Valabrega G, Montemurro F, Aglietta M Trastuzumab, (2007) mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 1: 17-17.
19. Yarden Y, Sliwkowski MX, (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137.
20. Tomita K, Plager JE, (1979) In vivo cell cycle synchronization of the murine sarcome 180 tumor following alternating periods of hydroxyurea blockade and release. Cancer Res 39: 4407-4411.
21. Ashkenazi R, Gentry SN, Jackson TL, (2008) Pathways to tumorigenesis - modeling mutation acquisition in stem cells and their progeny. Neoplasia 10: 1170-1182.
22. Morrison SJ, Kimble J, (2006) Asymmetric and symmetric stem-cell divisions in development and cancer. Nature 441: 1068-1074.
23. Sottoriva A, Vermeulen L, Tavare S, (2011) Modeling evolutionary dynamics of epigenetic mutations in hierarchically organized tumors. PLoS Comput Biol 7: e1001132.
24. Abkowitz JL, Catlin S, McCallie MT, Guttorp P, (2002) Evidence that the number of hematopoietic stem cells per animal is conserved in mammals. Blood 100: 2665-2667.
25. Padhani AR, Ollivier L, (2001) The RECIST criteria: implications for diagnostic radiologists. Br J Radiol 74: 983-986.
26. Chaffer CL, Brueckmann I, Scheel C, Kaestli AJ, Wiggins PA, et al. (2011) Normal and neooplastic nonstem cells can spontaneously convert to a stem-like state. Proc Nat Acad Sci 108: 7950-7955.
27. Gupta PB, Fillmore CM, Jiang G, Shapira SD, Tao K, et al. (2011) Stochastic state transitions give rise to phenotypic equilibrium in populatinos of cancer cells. Cell 146: 633-644.
28. Ashkenazi R, Jackson TL, Dontu G, Wicha MS, (2007) Breast cancer stem cells-research opportunities utilizing mathematical modeling. Stem Cell Rev 3: 176-182.
29. Enderling H, Chaplain MA, Anderson AR, Vaidya JS, (2007) A mathematical model of breast cancer development, local treatment and recurrence. J Theor Biol 246: 245-259.